Know Cancer

or
forgot password

A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily With Placebo in Patients With Non-Metastatic Prostate Cancer.


Phase 3
18 Years
N/A
Not Enrolling
Male
Non-Metastatic Prostate Cancer

Thank you

Trial Information

A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily With Placebo in Patients With Non-Metastatic Prostate Cancer.


Inclusion Criteria:



- Clinical diagnosis of non-metastatic cancer of the prostate gland

- Patient to be 18 years and above

Exclusion Criteria:

- Previous systemic therapy for prostate cancer

- Previous history of another form of cancer (not prostate) within 5 years of study
start.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Survival

Outcome Time Frame:

Throughout study period

Safety Issue:

No

Principal Investigator

Peter Iversen, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Department of Urology Rigshospitalet Copenhagen, Denmark

Authority:

Denmark: Danish Dataprotection Agency

Study ID:

D6876C00025

NCT ID:

NCT00672282

Start Date:

October 1995

Completion Date:

August 2008

Related Keywords:

  • Non-Metastatic Prostate Cancer
  • androgen antagonists
  • prostate neoplasms
  • Prostatic Neoplasms

Name

Location